The first prescription drug treatment for obstructive sleep apnea (OSA) has been approved by the Food and Drug Administration (FDA). Zepbound® (tirzepatide) was approved on Dec. 20, 2024, for moderate to severe obstructive sleep apnea in adults with obesity. Zepbound is one of many glucagon-like peptide-1 receptor agonists (GLP-1s). This expands Zepbound’s indications, which was initially approved for chronic weight management in adults with a weight-related comorbid condition. It contains the same active ingredient as Mounjaro®, a drug used to improve glycemic control in adults with type 2 diabetes.
Download our white paper to explore:
- The critical factors influencing benefits decisions
- A summary of Zepbound’s clinical trial results for treating OSA
- Health implications of OSA
- Strategic guidance for managing potential coverage and costs.
